Silence Therapeutics Share Discussion Threads

[volsung] 22/8/2017 08:11

Pleasant start to the day

[gersemi] 22/8/2017 08:04

She's off again

[rogen83] 21/8/2017 17:16

The quieter the better

[1gw] 21/8/2017 16:19

I am surprised we haven't had a rush of short-term players to the bulletin boards, given the share price chart. All the better for the future, perhaps, if the share price has done what it has done without much input from the bulletin boards or twitter.

[rogen83] 21/8/2017 09:43

On the move. Takeover at £2.50 would be nice

[1gw] 21/8/2017 09:38

Nice to see some 150's go through.

[1gw] 18/8/2017 15:13

Arrowhead on a tear again this afternoon.

[1gw] 17/8/2017 16:29

OK. Thanks. I'd forgotten that. I'll edit the earlier post.

[callumross] 17/8/2017 16:00

Sarossa is one of Richard Griffiths vehicles 1gw so think you have double counted that 3% but take your point entirely that there is little free float for PI's

[1gw] 17/8/2017 15:21

[Edited to remove comment about director/PDMR (replacement RNS issued) and correct for RG's control of Sarossa.]

The shareholder register looks pretty full. Not a lot of space for smaller PI's or new institutions. As far as I can see RG is the only major shareholder to have declared a change in position this year and he has managed to go from 25% at 31/12/16 (according to the annual report and including the Sarossa holding which now counts as a controlled interest for him) to 27% now.

I think the full list, from the AR plus RG's holdings notices is now:

27% Richard Griffiths
17% Robert Keith
12% Invesco
8% Henderson
6% Aviva
6% Woodford
3% Mortazavi
2% Simpson Financial
2% Robert Quested

Which adds (subject to rounding error) to a staggering 83%. I suppose the two 2% holders may have reduced or sold out without notification, but even so, nearly 80% of the shares held by 7 known entities is pretty impressive.

And that's before we see the impact of any new US investors trying to build a position following the Boston presentation.

It seems to be set up to drive the price higher through the constant PR on progress on patents and the potential for fees from existing competitor programs, Ali's comments on the potential valuation impact of those fees and now the US investor relations push.

I will hold on for the ride for now, I think. Arrowhead investor/analyst day coming up on 14th September and then Silence R&D day sometime in Q4.

[callumross] 17/8/2017 14:08

Richard Griffiths still upping his stake. Still seeing value at these levels.

[waterloo01] 11/8/2017 16:27

This is interesting. Via Dirk. Everyone's very litigious.

[1gw] 10/8/2017 22:05

The presentation is now on the website and it looks like Ali did indeed hit the patent issue fairly hard.

Last slide "Value inflexion points and upside risk" is perhaps the single most important one from the point of view of selling the proposition to new investors.

Hope for some follow-through buying in the coming days.

[1gw] 10/8/2017 15:41

Ali should have started his pitch to the Boston crowd by now. Can't see any sign of the presentation on the SLN site yet.

In the meantime ARWR has fallen back to earth - currently $1.81 down from a high of $2.17 on 7th August.

[1gw] 08/8/2017 10:07

I'm trying to resist the temptation to sell at the moment. It seems to me Thursday's presentation should be a positive (hopefully tempting in some new US investors) and then if I can wait that long the Arrowhead analyst day on 14th September could also give a boost to SLN via its holding in Arrowhead. And in the meantime the Arrowhead price already seems to have some good momentum, possibly in anticipation of that analyst day.

So I would at least like to give it a bit of time after Thursday to see if there is any new buying pressure.

No advice intended of course.

[volsung] 08/8/2017 09:30

Not selling to £2.50

[gersemi] 08/8/2017 09:29

She's not messing about is she though of course SLN's always been illiquid so contributing to its volatile nature

[waterloo01] 08/8/2017 09:28

Can't complain with a 50% rise in short order. I've sold for now but wish all best of luck here. Something seems to be brewing and a merger would be most likely bet.

[1gw] 08/8/2017 09:19

This is rather nice...

[volsung] 08/8/2017 09:19

Interesting spike there

[rogen83] 07/8/2017 21:54

$2.06 now

Things heating up

[1gw] 07/8/2017 16:22

Made it back to $2 now. Good volume the last couple of days on ARWR as well.

Over to Ali now to sell the merits of SLN to potential investors in Boston on Thursday.

[callumross] 07/8/2017 15:59

And off we go again - Arrowhead currently trading at 1.96 I see.

[1gw] 04/8/2017 07:28

The last ARWR after-hours trade was $1.77 I think, but not a lot of volume after hours so I don't know how good a guide that will be to today's ARWR open.


The conference call itself was short and sweet, with the focus on their analyst/investor day scheduled for 14th September. It sounds exciting and a couple of extracts from the Seeking Alpha transcript were as follows:

"Our plan has been to hold an Analyst R&D Day, to provide comprehensive update about the technology and our lead programs. We think the most effective time to hold this event is when our data across multiple programs have sufficiently matured and when we are in reasonable proximity to file with the regulators to start first in human studies, we are just about there. "

and

"We have always believed that for RNAi to achieve its full potential as an important new therapeutic modality, it must address diseases beyond the liver. Arrowhead is leading this expansion with TRMs targetable to new organ systems and it's as matured from goal to reality. We think this represents a giant leap forward for the field and we believe presents a host of new opportunities unique to Arrowhead."

There was no mention of the Silence stake.

Whole transcript is available here:

[callumross] 03/8/2017 23:33

Arrowhead up 9% after hours to 1 dollar 84 cents following their conference call.